Coherus Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Coherus Oncology (CHRS).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$7Upside to Avg. PT+419.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	Guggenheim	Paul Jeng	PT Cut	Buy	$12→$10
May 11, 2026	Guggenheim	—	Initiate	Buy	$12
Jan 22, 2026	Oppenheimer	Jay Olson	Initiate	Outperform	$10
Sep 4, 2025	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$4
Apr 29, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$7
Apr 24, 2025	UBS	Ashwani Verma	PT Cut	Neutral	$2→$1
Mar 11, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$7
Jan 23, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$7
Dec 5, 2024	Baird	Colleen Kusy	PT Raise	Outperform	$4→$6
Dec 4, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$7
Nov 8, 2024	Baird	Colleen Kusy	PT Cut	Outperform	$8→$4
Nov 7, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$12
Sep 16, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$12
Aug 16, 2024	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$4→$2
Aug 5, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$12
Jul 1, 2024	Baird	Colleen Kusy	PT Cut	Outperform	$9→$8
May 24, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$12
May 13, 2024	Truist Securities	Robyn Karnauskas	PT Cut	Buy	$8→$7
May 10, 2024	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$11→$12
Mar 20, 2024	HC Wainwright & Co.	Douglas Tsao	PT Cut	Buy	$13→$11

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

Guggenheim initiates coverage on Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Avi Kapoor

PRO
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

Maxim Group analyst Jason McCarthy upgrades Coherus Oncology (NASDAQ:CHRS) from Hold to Buy and announces $4 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $7 price target.

Benzinga Newsdesk

Coherus Oncology Inc

Coherus Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PRO
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PRO
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

People Also Watch

People Also Watch

Coherus Oncology Inc

Coherus Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PROGuggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PROMaxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

PROHC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

PROHC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

PRO
Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

PRO
Maxim Group Upgrades Coherus Oncology to Buy, Announces $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target